The British government announced Wednesday that a human challenge study, which will see healthy young volunteers deliberated infected with the coronavirus, has been approved by an ethics committee.
Now, researchers are calling for volunteers, as the trials are slated to start within a month.
The study is being conducted through a partnership between Imperial College London, the government’s Vaccines Taskforce, the Royal Free London NHS Foundation Trust and the clinical company hVIVO. Up to 90 healthy volunteers are needed, according to a press release from Open Orphan, the parent company of hVIVO.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
